ANIX Anixa Biosciences Inc

Price (delayed)

$2.67

Market cap

$92.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.32

Enterprise value

$91.6M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 27
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in ...

Highlights
The debt has decreased by 18% YoY and by 5% from the previous quarter
The company's quick ratio fell by 13% QoQ but it rose by 2.3% YoY
ANIX's EPS is up by 9% year-on-year but it is down by 3.2% since the previous quarter
The equity has contracted by 13% YoY

Key stats

What are the main financial stats of ANIX

ANIX stock price

How has the Anixa Biosciences stock price performed over time
Intraday
-5.99%
1 week
-11.59%
1 month
-3.26%
1 year
-40.93%
YTD
-14.42%
QTD
-8.87%

Financial performance

How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.98M
Net income
-$10.38M
Gross margin
N/A
Net margin
N/A
ANIX's operating income is up by 8% year-on-year but it is down by 2.8% since the previous quarter
The net income has increased by 7% year-on-year but it has declined by 3.5% since the previous quarter

Price vs fundamentals

How does ANIX's price correlate with its fundamentals

Growth

What is Anixa Biosciences's growth rate over time

Valuation

What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
6.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is up by 9% year-on-year but it is down by 3.2% since the previous quarter
The price to book (P/B) is 18% higher than the 5-year quarterly average of 5.3 but 18% lower than the last 4 quarters average of 7.7
The equity has contracted by 13% YoY

Efficiency

How efficient is Anixa Biosciences business performance
Anixa Biosciences's return on invested capital has decreased by 16% YoY and by 8% QoQ
The company's return on assets fell by 15% YoY and by 8% QoQ
The return on equity has declined by 11% year-on-year and by 7% since the previous quarter

Dividends

What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIX.

Financial health

How did Anixa Biosciences financials performed over time
ANIX's total liabilities is down by 16% YoY but it is up by 14% QoQ
Anixa Biosciences's total assets has decreased by 15% YoY
The debt is 99% less than the equity
The debt has decreased by 18% YoY and by 5% from the previous quarter
The equity has contracted by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.